Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Department of Dermatology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Clin Immunol. 2023 Aug;253:109694. doi: 10.1016/j.clim.2023.109694. Epub 2023 Jul 9.
Palmoplantar pustulosis (PPP), a chronic and stubborn skin disease, is mainly confined to the palms or/and soles, making it possible for localized use of therapeutic antibodies. In this real-world prospective cohort study, 8 patients with PPP received palms/soles injections of ixekizumab (0.8 mg in 0.1 ml) every 2 to 8 weeks due to the COVID-19 pandemic. The treatment endpoint was a 75% improvement from baseline in Palmoplantar Pustulosis/Psoriasis Area and Severity Index (PPPASI 75). At week 8, 75%, 50% and 12.5% of 8 patients reached PPPASI 50, PPPASI 75 and PPPASI 90. At week 12, 100%, 75% and 25% of 8 patients reached PPPASI 50, PPPASI 75 and PPPASI 90. This is the first study to evaluate the efficacy and safety of local injection of micro-dose ixekizumab for PPP in real clinical practice. A high proportion of patients rapidly achieved PPPASI 75, and maintained long-term efficacy with satisfactory safety.
掌跖脓疱病（PPP）是一种慢性且顽固的皮肤病，主要局限于手掌或/和足底，因此可以局部使用治疗性抗体。在这项真实世界的前瞻性队列研究中，由于 COVID-19 大流行，8 例 PPP 患者每 2 至 8 周接受 ixekizumab（0.1ml 中 0.8mg）手掌/足底注射。治疗终点是 Palmoplantar Pustulosis/Psoriasis Area and Severity Index（PPPASI 75）自基线改善 75%。第 8 周时，8 例患者中有 75%、50%和 12.5%达到 PPPASI 50、PPPASI 75 和 PPPASI 90。第 12 周时，8 例患者中有 100%、75%和 25%达到 PPPASI 50、PPPASI 75 和 PPPASI 90。这是第一项评估真实临床实践中微剂量 ixekizumab 局部注射治疗 PPP 的疗效和安全性的研究。很大比例的患者迅速达到 PPPASI 75，并且具有长期疗效和满意的安全性。
